NewAmsterdam Pharma Co N.V.
NAMSDrugs in Pipeline
8
Phase 3 Programs
4
Upcoming Catalysts
5
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
5 upcoming, 3 past
How NAMS's past catalysts played out
obicetrapib 10 mg + ezetimibe 10 mg FDC daily
Lipidemia
Monotherapy obicetrapib
Dyslipidemias
Obicetrapib
Dyslipidemias
Obicetrapib 10 mg
Lipidemia
obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
Dyslipidemias
Obicetrapib 5mg
Dyslipidemias
Ezetimibe 10mg
Dyslipidemias
Obicetrapib 10mg
Antioxidant Absorption
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
obicetrapib 10 mg + ezetimibe 10 mg FDC daily | Phase 3 | Lipidemia | - | - |
Monotherapy obicetrapib | Phase 3 | Dyslipidemias | - | - |
Obicetrapib | Phase 3 | Dyslipidemias | - | - |
Obicetrapib 10 mg | Phase 3 | Lipidemia | - | - |
obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks | Phase 2 | Dyslipidemias | - | - |
Obicetrapib 5mg | Phase 2 | Dyslipidemias | - | - |
Ezetimibe 10mg | Phase 2 | Dyslipidemias | - | - |
Obicetrapib 10mg | Phase 2 | Antioxidant Absorption | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in NewAmsterdam Pharma Co N.V.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in NewAmsterdam Pharma Co N.V.'s (NAMS) pipeline across Phase 3, Phase 2. Its lead program is obicetrapib 10 mg + ezetimibe 10 mg FDC daily (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is NewAmsterdam Pharma Co N.V.'s next FDA catalyst?→
NewAmsterdam Pharma Co N.V.'s (NAMS) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NAMS biotech catalysts?→
Add NAMS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NewAmsterdam Pharma Co N.V.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.